DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for chronic venous insufficiency — screening already-approved drugs against its 9-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleChronic venous insufficiency maps to a 9-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for chronic venous insufficiency is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase (ABO) — ABO is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 6-deoxy-alpha-l-galactopyranosyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4Y63 · 1.3 Å · ligand octyl 2-O-(6-deoxy-alpha-L-galactopyranosyl)-beta-D-galactopyranoside (BHE). Experimental structure, not a prediction.
What the evidence adds up to
A 2018 review of pharmacotherapy for chronic venous insufficiency states that venoactive drugs are a main principle of conservative treatment for both small and complicated forms, and that effectiveness is largely associated with the choice of phlebotrophic drug. The review discusses approaches to systemic and topical drug therapy depending on the form and stage of the disease. No specific drug names, response rates, or sample sizes are given in that abstract.
A 2000 review notes that elevated venous pressure is a hallmark of chronic venous insufficiency, but that no direct link at the cellular and molecular levels between venous hypertension and actual tissue damage has been established. It discusses evidence for an inflammatory reaction and several molecular alterations in the development of the condition. The abstract calls for development of experimental models, analysis of mechanical tissue stresses in addition to venous hypertension, and systematic studies of clinically stratified and standardised patient-derived samples.
A 2025 scoping review aims to systematically identify, describe, and map functional assessment instruments used in patients with chronic venous insufficiency, and to examine how well these instruments address key functional domains. It also aims to identify gaps in measurement that may inform future research and clinical practice. No results, numbers, or conclusions about any instrument’s performance are reported in the abstract.
What is still missing is a molecular description of the pathogenesis that links venous hypertension to tissue damage, validated functional assessment instruments that cover all relevant domains, and any clinical trial data that tests specific venoactive drugs against placebo or other treatments in a stratified patient population. Money for those trials and for the development of standardised patient-derived samples is also missing.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Ambulatornaya khirurgiya = Ambulatory Surgery (Russia) · 2018 · 4 citations · open access
Pharmacotherapy of chronic venous insufficiency of the lower extremities
AbstractChronic venous insufficiency (CVI) is the most common pathology of the peripheral vascular system. One of the main principles of conservative treatment for both small and complicated forms is pharmacotherapy with the use of venoactive drugs. The effectiveness of therapy is largely associated with the choice of phlebotrophic drug. The article discusses approaches to systemic and topical drug therapy depending on the form and stage of CVI.
Microcirculatory Inflammation in Chronic Venous Insufficiency: Current Status and Future Directions
AbstractOne of the hallmarks of chronic venous insufficiency (CVI) is an elevated venous pressure. However, no direct link at the cellular and molecular levels between venous hypertension and actual tissue damage in CVI has been established. Evidence for generation of an inflammatory reaction and several molecular alterations in the development of CVI is discussed. Development of experimental models of CVI, analysis of the mechanical tissue stresses in addition to venous hypertension, in combination with systematic studies of clinically stratified and standardized patient-derived samples is required for molecular description of the pathogenesis of CVI.
Measurement Instruments for Assessing Functional Impairments in Patients with Chronic Venous Insufficiency: A Scoping Review
AbstractThis scoping review aims to systematically identify, describe, and map the functional assessment instruments used in individuals with chronic venous insufficiency (CVI). Additionally, it seeks to examine the extent to which these instruments address key functional domains relevant to CVI and to identify potential gaps in measurement that may inform future research and clinical practice.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
